Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TB 402

Known as: TB-402, TB402 monoclonal antibody 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial.
TB-402 is a long-acting monoclonal antibody that partially inhibits factor VIII. A single administration of TB-402 was effective… Expand
Is this relevant?
2012
2012
Antidote strategies to reverse anticoagulation with TB-402, a long-acting partial inhibitor of factor VIII.
BACKGROUND TB-402 is a partially inhibiting antibody of factor VIII that is under development as a long-acting anticoagulant… Expand
Is this relevant?
2012
2012
Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis.
INTRODUCTION Partial inhibition of Factor VIII (FVIII) may provide antithrombotic efficacy whilst avoiding excessive… Expand
Is this relevant?
2011
2011
Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial.
BACKGROUND TB-402 is a novel anticoagulant monoclonal antibody with a prolonged antithrombotic effect resulting from its partial… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
Review
2011
Review
2011
New parenteral anticoagulants in development
The therapeutic armamentarium of parenteral anticoagulants available to clinicians is mainly composed by unfractionated heparin… Expand
  • figure 1
  • table 2
  • table 3
Is this relevant?
2011
2011
Effects of a FVIII inhibitor TB-402 on coagulation: reversibility with pro-coagulants
 
Is this relevant?
2010
2010
Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
BACKGROUND TB-402, a human monoclonal antibody that partially inhibits Factor VIII activity (FVIII:C), is being developed as a… Expand
Is this relevant?
2010
2010
Single intravenous administration of TB-402 for the prophylaxis of VTE after total knee replacement surgery
Total VTE was lower in each of the TB-402 groups compared to the enoxaparin group: 16.7% (9.8-26.9), 23.9% (15.3-35.3), 24.1%(16… Expand
Is this relevant?
2009
2009
Thrombogram analysis of the long-acting anticoagulant effect of TB-402, a human anti-FVIII antibody, and of its interactions with rHVFIII, LMWH and Warfarin in healthy volunteers
 
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE